

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Andrew R. Marks et al.	Confirmation No.:	7653
Application No.:	10/809,089	Art Unit:	1612
Filed:	March 25, 2004	Examiner:	B. J. Packard
Title:	NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) AND USES THEREOF		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Applicants state that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing date of this Information Disclosure Statement. No fee is required.

Enclosed please find a copy of the Extended European Search Report corresponding to European Application No 09166965.5, received on October 20, 2009.

The item marked CA is provided in a non-English language and was cited in the extended European Search Report corresponding to European Patent Application No 09166965.5 for showing the synthesis of 1,4-benzothiazepines.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 0019240.00596US1 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: November 19, 2009

/Jane M. Love, Ph.D./
Jane M. Love, Ph.D.
Registration No.: 42,812
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
1875 Pennsylvania Avenue, NW
Washington, DC 20006
(202) 663-6000 (telephone)
(202) 663-6363 (facsimile)